A Phase II, Single-arm, Open-label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients With Stage IV Metastatic Pancreatic Adenocarcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Dec 2016
At a glance
- Drugs PBI 05204 (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Phoenix Biotechnology
- 10 Jun 2017 Biomarkers information updated
- 28 Sep 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016.
- 28 Sep 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Dec 2016.